Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors - PubMed

Affiliations

• PMID: 12815379
• DOI: 10.1038/nrd1112

Review

Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors

Jonathan A Tobert. Nat Rev Drug Discov. 2003 Jul.

Abstract

In the 1950s and 1960s, it became apparent that elevated concentrations of plasma cholesterol were a major risk factor for the development of coronary heart disease, which led to the search for drugs that could reduce plasma cholesterol. One possibility was to reduce cholesterol biosynthesis, and the rate-limiting enzyme in the cholesterol biosynthetic pathway, 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, was a natural target. Here, I describe the discovery and development of lovastatin--the first approved inhibitor of HMG-CoA reductase--and the clinical trials that have provided the evidence for the ability of drugs in this class to reduce the morbidity and mortality associated with cardiovascular disease.

Similar articles

• Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.

  Pappu AS, Bacon SP, Illingworth DR. Pappu AS, et al. J Lab Clin Med. 2003 Apr;141(4):250-6. doi: 10.1067/mlc.2003.31. J Lab Clin Med. 2003. PMID: 12677170

• Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.

  McAnally JA, Gupta J, Sodhani S, Bravo L, Mo H. McAnally JA, et al. Exp Biol Med (Maywood). 2007 Apr;232(4):523-31. Exp Biol Med (Maywood). 2007. PMID: 17392488

• Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs.

  Manzoni M, Rollini M. Manzoni M, et al. Appl Microbiol Biotechnol. 2002 Apr;58(5):555-64. doi: 10.1007/s00253-002-0932-9. Epub 2002 Feb 14. Appl Microbiol Biotechnol. 2002. PMID: 11956737 Review.

• [Treatment of hyperlipidemia with HMG-CoA reductase inhibitors].

  Prager R. Prager R. Wien Med Wochenschr Suppl. 1989;105:17-20. Wien Med Wochenschr Suppl. 1989. PMID: 2694627 Review. German.

Cited by

• Crystal structure and biochemical studies of the trans-acting polyketide enoyl reductase LovC from lovastatin biosynthesis.

  Ames BD, Nguyen C, Bruegger J, Smith P, Xu W, Ma S, Wong E, Wong S, Xie X, Li JW, Vederas JC, Tang Y, Tsai SC. Ames BD, et al. Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11144-9. doi: 10.1073/pnas.1113029109. Epub 2012 Jun 25. Proc Natl Acad Sci U S A. 2012. PMID: 22733743 Free PMC article.

• A highly productive, whole-cell DERA chemoenzymatic process for production of key lactonized side-chain intermediates in statin synthesis.

  Ošlaj M, Cluzeau J, Orkić D, Kopitar G, Mrak P, Casar Z. Ošlaj M, et al. PLoS One. 2013 May 7;8(5):e62250. doi: 10.1371/journal.pone.0062250. Print 2013. PLoS One. 2013. PMID: 23667462 Free PMC article.

• Production and Selectivity of Key Fusarubins from Fusarium solani due to Media Composition.

  Kristensen SB, Pedersen TB, Nielsen MR, Wimmer R, Muff J, Sørensen JL. Kristensen SB, et al. Toxins (Basel). 2021 May 25;13(6):376. doi: 10.3390/toxins13060376. Toxins (Basel). 2021. PMID: 34070644 Free PMC article.

• Zinc-Mediated Transformation of 1,3-Diols to Cyclopropanes for Late-Stage Modification of Natural Products and Medicinal Agents.

  McGinnis TM, Thane TA, Jarvo ER. McGinnis TM, et al. Org Lett. 2022 Aug 5;24(30):5619-5623. doi: 10.1021/acs.orglett.2c02362. Epub 2022 Jul 22. Org Lett. 2022. PMID: 35867876 Free PMC article.

• Statin tolerability: In defence of placebo-controlled trials.

  Tobert JA, Newman CB. Tobert JA, et al. Eur J Prev Cardiol. 2016 May;23(8):891-6. doi: 10.1177/2047487315602861. Epub 2015 Aug 28. Eur J Prev Cardiol. 2016. PMID: 26318980 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information